Efficacy prediction and molecular mechanism of thyroid hormone levels and multi-target TKI therapy for renal cell carcinoma and hepatocellular carcinoma

doi:10.3760/cma.j.issn.1673-422X.2019.05.011

Abstract

Abstract: Hypothyroidism is a common adverse reaction in clinical multi-target tyrosine kinase inhibitor (TKI) and may be used as a predictor of efficacy of TKI drugs. Studies show that hypothyroidism is significantly associated with good prognosis in patients with renal cell carcinoma treated with multi-target TKI, which may be related to inhibition of vascular endothelial growth factor receptor pathway, potential offtarget effects and inhibition of cell proliferation. Whereas in the patients with hepatocellular carcinoma who received multi-target TKI therapy, hypothyroidism is an indicator of poor prognosis, which is related to the T3/TR pathway regulating liver cancer growth and invasion. The predictive function and mechanism of thyroid hormone levels in different tumor patients receiving multi-target TKI drugs are different, and further research is still needed.

Key words: Thyroid hormones, Neoplasms, Prognosis, Tyrosine kinase inhibitors

Sun Yueqin, Li Aimin, Luo Yue, Song Zhenghui, Zhuang Xuefen, Dai Guanqi, Liu Xinhui. Efficacy prediction and molecular mechanism of thyroid hormone levels and multi-target TKI therapy for renal cell carcinoma and hepatocellular carcinoma[J]. Journal of International Oncology, 2019, 46(5): 303-306.

References

［1］ Shi XZ, Jin X, Xu P, et al. Relationship between breast cancer and levels of serum thyroid hormones and antibodies: a metaanalysis［J］. Asian Pac J Cancer Prev, 2014, 15(16): 6643-6647. ［2］ Prinzi N, Sorrenti S, Baldini E, et al. Association of thyroid diseases with primary extrathyroidal malignancies in women: results of a cross-sectional study of 6,386 patients［J］. PLoS One, 2015, 10(3): e122958. DOI: 10.1371/journal.pone.0122958. ［3］ Pinter M, Haupt L, Hucke F, et al. The impact of thyroid hormones on patients with hepatocellular carcinoma［J］. PLoS One, 2017, 12(8): e0181878. DOI: 10.1371/journal.pone.0181878. ［4］ Borriello A, Caldarelli I, Bencivenga D, et al. Tyrosine kinase inhibitors and mesenchymal stromal cells: effects on selfrenewal, commitment and functions［J］. Oncotarget, 2017, 8(3): 5540-5565. DOI: 10.18632/oncotarget.12649. ［5］ Jiao Q, Bi L, Ren Y, et al. Advances in studies of tyrosine kinase inhibitors and their acquired resistance［J］. Mol Cancer, 2018, 17(1): 36. DOI: 10.1186/s12943-018-0801-5. ［6］ Qin S, Li A, Yi M, et al. Recent advances on antiangiogenesis receptor tyrosine kinase inhibitors in cancer therapy［J］. J Hematol Oncol, 2019, 12(1): 27. DOI: 10.1186/s13045-019-0718-5. ［7］ Beukhof CM, van Doorn L, Visser TJ, et al. Sorafenibinduced changes in thyroid hormone levels in patients treated for hepatocellular carcinoma［J］. J Clin Endocrinol Metab, 2017, 102(8): 2922-2929. DOI: 10.1210/jc.2016-4025. ［8］ Mondello P, Mian M, Pitini V, et al. Thyroid hormone autoantibodies: are they a better marker to detect early thyroid damage in patients with hematologic cancers receiving tyrosine kinase inhibitor or immunoregulatory drug treatments?［J］. Curr Oncol, 2016, 23(3): e165-e170. DOI: 10.3747/co.23.3026. ［9］ Motzer RJ, Jonasch E, Agarwal N, et al. Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology［J］. J Natl Compr Canc Netw, 2017, 15(6): 804-834. DOI: 10.6004/jnccn.2017.0100. ［10］ Wolter P, Stefan C, Decallonne B, et al. Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients with advanced renal cell cancer (RCC)［J］. J Clin Oncol, 2008, 26(15_Suppl): 5126. DOI: 10.1200/jco.2008.26.15_suppl.5126. ［11］ Riesenbeck LM, Bierer S, Hoffmeister I, et al. Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib［J］. World J Urol, 2011, 29(6): 807-813. DOI: 10.1007/s00345-010-0627-2. ［12］ Nearchou A, Valachis A, Lind P, et al. Acquired hypothyroidism as a predictive marker of outcome in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: a literature-based meta-analysis［J］. Clin Genitourin Cancer, 2015, 13(4): 280-286. DOI: 10.1016/j.clgc.2014.10.002. ［13］ Lechner MG, Vyas CM, Hamnvik OR, et al. Hypothyroidism during tyrosine kinase inhibitor therapy is associated with longer survival in patients with advanced nonthyroidal cancers［J］. Thyroid, 2018, 28(4): 445-453. DOI: 10.1089/thy.2017.0587. ［14］ Wang T, Xia L, Ma S, et al. Hepatocellular carcinoma: thyroid hormone promotes tumorigenicity through inducing cancer stem-like cell self renewal［J］. Sci Rep, 2016, 6: 25183. DOI: 10.1038/srep25183. ［15］ Zhang N, Jin W, Zhou S, et al. Hypothyroidism is associated with worse outcomes of hepatocellular carcinoma patients after liver transplantation［J］. Cancer Med, 2018, 7(12): 5870-5878. DOI: 10.1002/cam4.1797. ［16］ Chu YD, Lin KH, Huang YH, et al. A novel thyroid function index associated with opposite therapeutic outcomes in advanced hepatocellular carcinoma patients receiving chemotherapy or sorafenib［J］. Asia Pac J Clin Oncol, 2018, 14(5): e341-e351. DOI: 10.1111/ajco.12983. ［17］ BudaNowak A, Kucharz J, Dumnicka P, et al. Sunitinibinduced hypothyroidism predicts progressionfree survival in metastatic renal cell carcinoma patients［J］. Med Oncol, 2017, 34(4): 68. DOI: 10.1007/s12032-017-0928-z. ［18］ White PT, Cohen MS. The discovery and development of sorafenib for the treatment of thyroid cancer［J］. Expert Opin Drug Discov, 2015, 10(4): 427-439. DOI: 10.1517/17460441.2015.1006194. ［19］ De Falco V, Carlomagno F, Li HY, et al. The molecular basis for RET tyrosinekinase inhibitors in thyroid cancer［J］. Best Pract Res Clin Endocrinol Metab, 2017, 31(3): 307-318. DOI: 10.1016/j.beem.2017.04.013. ［20］ Drui D, Illouz F, Do Cao C, et al. Expert opinion on thyroid complications of new anticancer therapies: tyrosine kinase inhibitors［J］. Ann Endocrinol (Paris), 2018, 79(5): 569-573. DOI: 10.1016/j.ando.2018.07.003. ［21］ Shu M, Zai X, Zhang B, et al. Hypothyroidism side effect in patients treated with sunitinib or sorafenib: clinical and structural analyses［J］. PLoS One, 2016, 11(1): e0147048. DOI: 10.1371/journal.pone.0147048. ［22］ Lin HY, Chin YT, Yang YC, et al. Thyroid hormone, cancer, and apoptosis［J］. Compr Physiol, 2016, 6(3): 1221-1237. DOI: 10.1002/cphy.c150035. ［23］ Czarnecka AM, Matak D, Szymanski L, et al. Triiodothyronine regulates cell growth and survival in renal cell cancer［J］. Int J Oncol, 2016, 49(4): 1666-1678. DOI: 10.3892/ijo.2016.3668. ［24］ Frau C, Loi R, Petrelli A, et al. Local hypothyroidism favors the progression of preneoplastic lesions to hepatocellular carcinoma in rats［J］. Hepatology, 2015, 61(1): 249-259. DOI: 10.1002/hep.27399. ［25］ Perra A, Plateroti M, Columbano A. T3/TRs axis in hepatocellular carcinoma: new concepts for an old pair［J］. Endocr Relat Cancer, 2016, 23(8): R353-R369. DOI: 10.1530/ERC-16-0152. ［26］ MartinezIglesias O, GarciaSilva S, Tenbaum SP, et al. Thyroid hormone receptor beta1 acts as a potent suppressor of tumor invasiveness and metastasis［J］. Cancer Res, 2009, 69(2): 501-509. DOI: 10.1158/0008-5472.CAN-08-2198. ［27］ Chung IH, Chen CY, Lin YH, et al. Thyroid hormonemediated regulation of lipocalin 2 through the Met/FAK pathway in liver cancer［J］. Oncotarget, 2015, 6(17): 15050-15064. DOI: 10.18632/oncotarget.3670. ［28］ Wu SM, Cheng WL, Liao CJ, et al. Negative modulation of the epigenetic regulator, UHRF1, by thyroid hormone receptors suppresses liver cancer cell growth［J］. Int J Cancer, 2015, 137(1): 37-49. DOI: 10.1002/ijc.29368. ［29］ Hercbergs AA, Goyal LK, Suh JH, et al. Propylthiouracilinduced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a phase Ⅰ/Ⅱ study［J］. Anticancer Res, 2003, 23(1B): 617-626.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[3]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[4]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[5]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[6]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[7]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[8]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[9]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[10]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[11]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[12]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[13]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[14]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[15]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.